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Ovarian carcinoma is generally resectable and chemotherapy
sensitive (Fennelley et al, 1995). In spite of these favourable char-
acteristics the overall cure rate for advanced stage III and IV
patients is approximately 20% (Oncolink, http://oncolink.com).
This is due to relapses as a result of expansion of chemoresistant
clones. Local immunotherapy is a candidate for an adjuvant treat-
ment (Willemse et al, 1990; Giannios et al, 1997). This option is
advocated by the local spread of the cancer in the majority of cases
and known cytokine generation potential of ovarian carcinoma
(Berek et al, 1991; Plante et al, 1994). Interteukin (IL)-6 is a hall-
mark cytokine of ovarian carcinoma (Berek et al, 1991; Plante et
al, 1994). However, it is not known whether: (i) IL-6 production is
associated with a specific histiotype of ovarian carcinoma, (ii) 
IL-6 modifies local immunity and (iii) is associated with biolog-
ical features of ovarian carcinoma affecting the progression of 
the disease. The present paper was aimed at addressing all of these
questions. It appeared that a high degree of IL-6 activity 
in peritoneal carcinomatous fluid (PCF) was seen predominately
in mucinous/serous cancers which lacked an accumulation of 
p53 and this cytokine exerted biological impact not only as a
factor inducing C-reactive protein (CRP) but also encouraging
influx/expansion of memory T- and B-cells.
PATIENTS AND METHODS
Thirty-five ovarian carcinoma patients (FIGO > IIB), five with
ovarian benign cyst and five with ascites in the course of gastro-
intestinal carcinoma were investigated. The patients did not
receive any treatment before the study. FIGO staging in ovarian
carcinoma patients was performed at surgery. Histopathology and
grading was performed according to the standard procedure using
paraffin-embedded tissue sections. Twenty-six patients were
eligible for surgical cytoreduction; in others laparotomy revealed
neoplastic mass considered unresectable (Table 1).
Cell isolation
PCF was aseptically obtained during surgery either from peri-
toneal cavity (24 patients) or from ovarian cysts (five patients) or
both (six patients). Volume of PCF ranged from 250 to 20 000 ml
and the cellularity from 1 ´ 107 to 1.2 ´ 108 cells ml–1 (mean 
2.3 ´ 108 cells ml–1). Volume (and cellularity) of cysts PCF ranged
from 150 to 3000 ´ 106 (1–8 ´ 106 cells ml–1).
Benign cysts fluid volume ranged from 100 to 5000 ml and
0.2–2 ´ 106 cells ml–1. Both, benign and carcinomatous fluids,
were centrifuged (250 g, 10 min at 4°C) to obtain cells and super-
natants for further study.
Peripheral blood was collected into lithium-heparin, EDTA and
serum collection tubes at the day of surgery for mononuclear cell
phenotype, RNA study and protein level measurements, respec-
tively.
Cell purification
PCF cellular pellet was resuspended in RPMI-1640 (5 ´ 106 cells
ml–1) and overlaid on two-step density gradient consisting of 100%
(density 1.077 g ml–1) and 75% (1.057 g ml–1) of Ficoll-Metrizoate
solution (Gradisol-L, Polfa, Kutno, Poland) and centrifuged 
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(MNC) and enriched with cancer cell fractions (Freedman et al,
1994). In five cases, cytokeratin 10 and HLA DR antigen (non-
polymorphic region) staining was performed in both upper
(enriched in cancer cells) and lower (PCF MNC) cell fractions.
This staining revealed that the upper fraction was from 50 
to 96% keratin-positive cells and from 5 to 30% HLA-DR+
cytokeratin–mesothelial-like cells (Figure 2). Cytofluorograph
analysis of lower interphase cells revealed that this fraction was
composed of lymphocytes: CD45bright+/CD14– [59.4% + 17.26
s.e.m.,  n = 16], granulocytes: CD45dimm+/CD14– [15.89% + 9.22
s.e.m., n = 16] and monocytes/macrophages: CD45+/CD14+ [24.7%
+ 11.6 s.e.m., n = 16]. Peripheral blood mononuclear cells (PBMC)
were isolated by standard one-step density gradient centrifugation
(1.077 g ml–1). All cell fractions (viability > 95% assessed by
trypan blue exclusion) were washed, resuspended in RPMI and
adjusted to the desired concentration.
Flow cytometry
One times 106 cells ml–1 of PCF MNC and PBMC were stained
with fluorescein isothiocyanate (FITC) or phycoerythrin (PE)-
conjugated monoclonal antibodies (mAb) specific for CD3, CD4,
CD8, CD16, CD56, CD57, CD22, CD45RO, CD25 and HLA-DR
(Becton-Dickinson), read in the Becton-Dickinson FACStar+
instrument and analysed with the use of PC-Lysis software. CD45
and CD14 mAb staining was usually used for leucocyte and
lymphocyte gating. CD14 was assessed in leucocyte gate,
CD45RO and HLA-DR in both leucocyte and lymphocyte gate, T,
B and NK cell markers staining was read in lymphocyte gate.
Serum and PCF protein measurements
Immunoglobulins (A, G and M), albumin and CRP levels were
according to the manufacturer’s instruction determined by the use
of a NBehring Laser nephelometer.
Cell lines
7TD1 was a gift from Prof. Van Snik, Ludwig Institute of Cancer
Research, Bruxelles; P388 and WEHI 164 were obtained from the
Institute of Immunology and Experimental Therapy Polish
Academy of Sciences, Wroclaw, Poland.
Assay for IL-6 biological activity
IL-6 level in PCF and serum were measured with the use of 7TD1
hybridoma cell line bioassay (Papadopoulos et al, 1995). 7TD1
cells at the concentration of 2.5 ´ 106 cells well–1 were plated in
96-well flat-bottomed plates. On day 2 of culture, serial dilutions
of experimental samples and standard supernatants and on day 
4, 30 ml of 3-(4,5-dimethylthiazal-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) were added to each well. Cells were then lysed
and collected fluid was read at 540 nm. Results were expressed in
units calculated as fraction of a standard sample concentration,
which caused 50% of maximal growth as assessed from the curve
after probite transformation of the original readings.
Specificity of the bioassay was validated with the use of anti-IL-
6 monoclonal antibody (clone BE-8, gift from Dominique Emilie,
INSERUM, Clamart, France). Eight randomly chosen PCF
samples with known IL-6 activity at the range from 1500 U ml–1 to
8000 U ml–1 were retested after prior to the bioassay 1 h 
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Table 1 Patient characteristics
Number of patients 35
Mean age 55 (32–84)
Histological type Serous 14 (40%)
Mucinous 4 (11%)
Endometrioid 6 (19%)
Undifferentiated 11 (30%)
Stage (FIGO): IIB 2
IIC 2
IIIA 3
IIIB 2
IIIC 19
IV 7
Ovarian carcinoma
Surgery Radical 12
Cytoreduction 14
Unable 9
Residual tumour: <5 cm 15
>5 cm 20
Material Peritoneal neoplastic effusion 27
Peritoneal neoplastic effusion and cyst fluid 4
Cyst fluid 4
Gastrointestial cancer
Number of patients 5
Mean age 51 (43–62)
Residual tumour: >5 cm 5
Material Peritoneal neoplastic effusion 5
Benign cyst
Mean age 47 (34–58)
Material Benign cysts fluid 5
/incubation at 37°C with neutralizing antibody (5mg ml–1).
Neutralization was seen in all tested samples independent on the
level of activity and ranged from 90% to 98%.
Assay for tumour necrosis factor a
Tumour necrosis factor a(TNF-a) level in PCF and serum was
measured based on WEHI 164 cell line (Boury et al, 1997). WEHI
164 fibroblast cells at a concentration of 4 ´105 cells well–1 were
plated in 96-well, flat-bottomed plates. When the monolayer of
WEHI 164 cells became confluent, 0.2mg ml–1 actinomycyne D
(Sigma), together with either recombinant TNF-aand experi-
mental samples were added. A 1-day culture (37°C, 5% carbon
dioxide) was followed by incubation with 30ml well–1 of MTT.
Finally, cells were lysed and samples read at 540nm and calcu-
lated with the use of a probite transformation.
WEHI cell line used in the bioassay was sensitive to recombi-
nant TNF-a(rTNF-a) at concentrations from 0.05pg ml–1 to 
700pg ml–1 and this sensitivity was abrogated by TNF-aneutral-
izing monoclonal antibody (clone: 1825.121, R&D Systems) at
concentration 5mg ml–1. TNF-aactivity found in two PCF retested
samples was neutralized above 90%.
Immunohistochemical staining of tumour tissue
paraffin sections and cytospins
Paraffin block tissue sections were microwave processed
(Cattoretti et al, 1992) and stained with the use of the three-step
immunoperoxidase technique based on Dako reagents and staining
system. Monoclonal, antibody for Ki-67 antigen (MIB1) was
kindly provided by J. Gerdes (Forschungs Institut Borstel,
Germany) and p53 was purchased from Dako (Clone DO-7). The
Ki-67 tumour positivity was graded according to the presence of
<10% (+), 10–50% (++) and >50% (+++) of positive cells. P53
expression was evaluated as positive when unequivocal staining
was seen and graded as – (no positive cells), + (few cells), ++ (less
than 50%) and +++ (majority of cells). All positive p53 tumours
showed nuclear staining. Cytospins were stained with the use of
the LSAB+ detection kit (Dako) for the presence of cytokeratin
(MNF116 mAb against cytokeratin 10, 17, 18, Dako) and HLA-
DR (Dako) positive cells.
Reverse transcriptase polymerase chain reaction
Total RNA was isolated with the use of guanidine isothio-
cyanate–phenol–chloroform extraction technique. Five microlitres
of RNA solution (electrophoretically proved to contain under-
gradated RNA) was subtracted to reverse transcriptase activity
(Stratagene). cDNA used for PCR was standardized against glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA. cDNA
was amplified (Biometra UNO II thermocycler) for GAPDH (35
cycles: 95°C: 30s, 68°C: 30s and 72°C: 45s) and for IL-6 (38
cycles: 95°C: 30s, 60°C: 30s and 72°C: 45s) in 25-ml reaction
mixture containing cDNA dilution, 0.125pMdNTP (Gibco-BRL),
1.25 unit of Taq-polymerase (Gibco-BRL), polymerase chain reac-
tion (PCR) Tris-HCl buffer (pH 8.3) and 25pMof 5¢and 
3¢sequence primers: (GAPDH: 5¢-AACAGCGACACCCACTC-
CTC-3¢, 5¢-GGAGGGGAGATTCAGTGTGTT-3¢; IL-6: 5¢-TAG-
CCGCCCCACACAGACAG-3¢, 5¢-GGCTGGCATTTGTTGTT-
GGG-3¢). PCR products (10ml) were electrophoresed in 1.5%
agarose gel and stained with ethidium bromide.
RESULTS
IL-6 PCF activity
Mean value +3 standard deviations (3 s.d.) of benign cyst fluid IL-
6 activity were considered as a limit of normality. IL-6 activity in
all five gastrointestinal cancers PCFs was above this limit. In 67%
of ovarian carcinoma patients, PCF IL-6 activity exceeded the
mean value +3 s.d. of gastrointestinal cancer PCF IL-6 activity.
The values above the latter limit were considered as specific for
ovarian carcinoma (Figure 1). IL-6 ovarian carcinoma PCF levels
were, in all cases, higher than those found in blood. PCF IL-6
levels and blood levels were merely correlated (r= 0.38, P=
0.076, n= 25).
IL-6 generation was associated with the histiotype of the
tumours being higher in serous or mucinous than in endometrioid
and undifferentiated tumours (Figure 1).
PCF IL-6 and TNF-aactivities were not correlated. The latter
inflammatory cytokine was found in all 12 except one ovarian
carcinoma PCF and this cytokine activity was correlated with
CD14+ cell proportions in PCF MNC (r= 0.88, P= 0.001).
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Figure 1IL-6 activity (7TD1 bioassay) in benign cyst fluid: BF (*), digestive
tract cancer peritoneal fluid: DT cancer (1), and ovarian carcinoma cyst fluid
ascites (s undifferentiated and nendometroid,l serous or m mucous). 
Mean 13 3s.d. of gastrointestinal cancer ascites value; 
Mean 13 3s.d. of benign cyst fluid valueNeutralizing antibody experiments validated the specificity of
the 7TD1 and WEHI 164 bioassays used in this study for IL-6 and
TNF-a activity measurements in PCF of ovarian cancer patients
respectively. In addition WEHI-cell line-based bioassay is not
affected by IL-6 and IL-1 (Eskandari et al, 1990), which are the
most commonly found cytokines in PCF of ovarian cancer
patients. Therefore, we can assume that the results of WEHI
bioassay reflected the presence of TNF-a in PCF. To identify more
directly cells producing IL-6, PCF cells obtained from ten patients
were discriminated into cancer and non-cancer mononuclear cell
enriched compartments (see the Methods section and Figure 2) for
mRNA study. In all situations IL-6 amplificats were found in
reverse transcription PCR (RT-PCR) of PCF cancer fraction popu-
lations. In contrast, PCF MNC IL-6 mRNA showed an absence of,
or much weaker levels of IL-6 amplificats (Figure 2).
Biological impact of PCF IL-6
Serum CRP levels were above the normal value range in 96%
ovarian carcinoma cases and were correlated with PCF IL-6 values
(r = 0.65, P = 0.0000, n = 25). To investigate the local effect of IL-
6 production phenotype, profile of PCF MNC was determined and
compared to that of blood. PCF MNC contained more CD14+ and
B lymphocytes (CD22+ or CD19+ cells) than PBMC. These differ-
ences probably contributed to the prevalence of HLA-DR+ cells in
PCF (Figure 3). In the T-cell compartment there were more CD4+
than CD8+ cells in PCF MNC as compared to blood which resulted
in a higher CD4/CD8 ratio in PCF MNC than in PBMC (4.8 + 0.94
vs 2.6 + 0.4, P = 0.03, Student’s t-test for paired samples). PCF
MNC had a higher proportion of CD45RO+ cells than that found
in PBMC but lower of CD56+ and CD57+ cells (Figure 3). To
address more directly the effect of IL-6 on cellular profile of PCF
MNC the coefficient of correlation between the proportions of
cells and the levels of IL-6 was calculated. It appeared that only
CD45RO but not all T- (CD3) or B- (CD19 or CD20) cell fractions
were positively correlated with the levels of IL-6 in PCF (r = 0.71,
P = 0.001, n = 21; Figure 4).
There was no direct association between the proportions of B-
cells and IL-6 levels. IL-6 supports B-cell differentiation, and
production of IgG is influenced to a larger degree than that of IgA
(Kishimoto, 1989). Therefore, IgG to IgA ratio was analysed in
PCF and serum. In PCF IgG: IgA was higher than that in blood
(3.8 + 0.5 vs 4.55 + 0.55, P = 0.001, Student’s t-test for paired
samples). There was a fair degree correlation between IL-6 ascites
level and preoperative platelet count (r = 0.26, P = 0.059).
Ki-67 and p53 positivity and histiotype of ovarian
carcinoma and IL-6 generation potential
Undifferentiated tumours had higher fractions of Ki-67+ cells and
p53+++ cells (unequivocally nuclear staining) than differentiated
adenocarcinomas (Figure 5). p53 extensive staining was inversely
correlated with IL-6 generation potential of ovarian carcinoma
tumours. The mean value of all PCF IL-6 levels was used as a cut-
off point to discriminate cases with tumours having higher (above
the mean) and lower IL-6 generation potential. It appeared that
tumours with p53+++ staining had IL-6 PCF levels more frequently
below this cut-off point than tumours with less pronounced p53
staining (10/15 vs 2/10, P = 0.03, Fisher’s exact test, Figure 6).
DISCUSSION
To survive in invaded tissue, carcinoma cells produce factors
enabling them accommodation, vascularization, growth and
metastasizing potential (Berger et al, 1995; Luca et al, 1997).
These substances frequently of cytokine-like characteristics
operate in an autocrine or paracrine fashion. IL-6 is known to be a
growth factor for some lymphomas (Hsu et al, 1993) and is
produced by some solid tumours, e.g. renal (Chang et al, 1997)
and ovarian carcinomas (Berek et al, 1991; Plante et al, 1994). IL-
6 has pleiotropic activity that includes reactivity with cancer cells
(Berger et al, 1995; Luca et al, 1997) and influences some body
systems in a distant way (Blay et al, 1997). It has been demon-
strated that ovarian carcinoma patients with a high serum IL-6
level had thrombocytosis and anaemia (Gastl et al, 1993).
However, little is known whether IL-6 generated locally site 
influences ovarian carcinoma cells and local immunity.
IL-6 is an immunostimulator enhancing expression of CD54
antigen (Hutchins et al, 1994) which may increase tumour–T-cell
interactions. These characteristics of IL-6 promoted some efforts
to transfect cancer cells with IL-6 gene to increase immunogenic
potential of carcinoma cells (Cao et al, 1996). Each manipulation
with a genome may in addition to introducing a given gene alter
the biology of transfected cell(s) thus the final effect of transfec-
tion depends on the function of the introduced gene and on the
non-specific alteration of cancer cells genome (Runnebaum,
1997). Therefore, tumours constitutively producing IL-6 can serve
as a model to study the influence of IL-6 on local and systemic
immune function in cancer patients.
In this study we analysed 35 patients with ovarian carcinoma.
Ovarian cells normally produce IL-6 and this ability may persist in
cancer cells originated from ovarian granulosa cells (Machelon 
et al, 1997). It has been previously reported that papillary ovarian
carcinoma are greater producers of IL-6 than non-papillary ones
(Kutteh, 1992) but the presence of association between the histio-
type and IL-6 production has not been so far shown. The present
study substantiated that IL-6 at significant concentration was seen
in PCF of serous-mucinous but not of less differentiated and
endometrioid carcinomas (Figure 1). This is a novel finding. The
presence of the association between the histiotype of ovarian
carcinoma and IL-6 levels also shows that IL-6 level depends on
the tumour histology but not at the stage or invasiveness of the
neoplastic process. Patients in all histiotype tumour categories did
not differ with respect to stage (Table 1). Similarly, carcinoma
ascites contained much less IL-6 than PCF of the majority of
mucinous/serous cancer patients (Figure 1). The ovarian carci-
noma cells origin of IL-6 was further indicated by the presence of
IL-6 mRNA in cell fraction enriched with carcinoma cells rather
than in PCF MNC fraction (Figure 2).
Mesothelial cells may also produce IL-6 (Offner et al, 1995) and
these cells were present in PCF cancer fractions (Figure 2). The
contribution of mesothelial cells to the ascites IL-6 should be
similar in ovarian carcinoma of different histiotype and in
gastrointestinal cancer. PFC cells profile of ovarian carcinoma
patients characterized with: (i) lower fraction of NK cells; this
represented more common phenomenon of depletion of cytotoxic
cells in cancer environment (Karimine et al, 1994; Matsuda et al,
1995), (ii) lower fraction of CD8+ CD3+ cells, this has also been
described in tumour infiltrating lymphocyte (TIL) population in
gynaecological cancers (Schondorf et al, 1997) and some colon
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Figure 2 Cytokeratin and HLA-DR positive cells in PCF MNC and tumour enriched fractions with respective content of GAPDH and IL-6 mRNA (numbers
reflect different patients tested). Unstained cells represent mesothelial, cancer cells and leucocytes in (i) cytokeratin and (ii) HLA-DR labelled tumour enriched
fraction and (iii) cytokeratin labelled PCF MNC fraction, respectively.carcinomas (Wimmenauer, 1994), (iii) an excess of CD19+/CD20+
and (iv) the higher fraction of CD45RO+ cells (Figure 3). The
latter two differences have not so far been defined and can be
attributed to the presence of IL-6 in ascites. The highest propor-
tions of CD19+/CD20+ cells were seen in ascites of serous/muci-
nous tumours that identified with a high IL-6 production (data not
shown). The proportion of CD45RO+ cells was directly correlated
with the PCF IL-6 levels (Figure 4). IL-6 influenced the local
immunity favouring B and T memory cells accumulation. These
differences might have their functional impact. Ovarian carcinoma
PCF immunoglobulins were preferably enriched in IgG. IL-6
injected intraperitoneally is able to augment the secondary
response to SRBC in mice more than tenfold (Takatsuki et al,
1988). Whether IL-6-dependent accumulation of CD45RO+ cells
reflected more refined immune system recognition of ovarian
carcinoma cells has still to be documented. However, it has been
illustrated that IL-6 in concert with TNF-a and IL-2 promotes
expansion of CD45RO+ cells even in the absence of antigen stimu-
lation (Unutmaz et al, 1994). In PCF TNF-a activity was found in
all 16 examined cases. IL-2 mRNA was seen in two out of three
samples studied so far (not shown).
The key question is whether IL-6 promotes ovarian carcinoma
cell proliferation. This was not the case because there was no asso-
ciation between the proportion of Ki-67+ cells and IL-6 activity
(Figure 5). However, p53 was less frequently accumulated in IL-6
producing tumours (Figure 6). The origin of this association,
which has not so far been reported, cannot be concluded from the
present study. This could be an indirect reflection of an association
between serous/mucinous histiotype with a high potential to
produce IL-6 (Figure 1) and a low degree of p53 accumulation
(Figure 6). However, an association between accumulation of p53
and local TNF-a activity has already been reported (Gotlieb et al,
1994). IL-6 was found to induce apoptosis associated with the 
activation of wild-type p53 in myeloid leukaemic cells (Yonish-
Rouach et al, 1991). Therefore, the local cytokine environment
may influence the susceptibility of cancer cells to the damage of
genome. In a recent published paper, Asschert et al (Asschert et al,
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Figure 5 Accumulation of p53 (A) and expression of Ki-67 antigen (B) in
ovarian carcinoma tumours1997) suggested that p53-positive tumours frequently express
cytokines. In the latter paper the Northern blot instead of a
bioassay or more sensitive RT-PCR was employed. The number of
cases was rather limited and the association was valid for
macrophage colony-stimulating factor but not IL-6 mRNA.
Data presented in this paper showed that patients characterized
either by high IL-6 production or by p53 accumulation prevailed in
the ovarian cancer group (18 out of 25, Figure 6). In the normal
epithelial cells IL-6 was found to increase bcl-2 expression
preventing apoptosis (Rollwagen et al, 1998). Bcl-2 mRNA is
present in a proportion of ovarian cancer tumours (Diebold et al,
1996; Herod et al, 1996 and own unpublished observation) and
was shown to be independent from p53 prognostic factor (Diebold
et al, 1996; Herod et al, 1996). Found in this study the inverse
correlation between p53 accumulation and IL-6 generation poten-
tial (Figure 6) suggests that in ovarian cancer population two 
independent mechanisms are involved in tumour survival. One is
involved with IL-6 production and the other with p53 mutation.
Hypothetically ovarian tumours take an advantage of any of these
two mechanisms to survive. Alternatively, the reported negative
association between p53 accumulation and high IL-6 generation
potential may only show that cancer cells with damaged genome,
which was reflected by the accumulation of p53, failed to maintain
the ability to produce constitutively IL-6.
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